These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17327290)

  • 1. Elevated creatine kinase and myalgia in a patient taking rosiglitazone.
    Kennie N; Antoniou T; Berger P
    Ann Pharmacother; 2007 Mar; 41(3):521-4. PubMed ID: 17327290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
    Ledl M; Hohenecker J; Francesconi C; Roots I; Bauer MF; Roden M
    Diabetologia; 2005 Oct; 48(10):1996-8. PubMed ID: 16132947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation thiazolidinediones and hepatotoxicity.
    Marcy TR; Britton ML; Blevins SM
    Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creatine kinase elevation, lactacidemia, and metabolic myopathy in adult patients with diabetes mellitus.
    Frank M; Finsterer J
    Endocr Pract; 2012; 18(3):387-93. PubMed ID: 22297056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma.
    El-Naggar MH; Helmy A; Moawad M; Al-Omary M; Al-Kadhi Y; Habib B
    Ann Pharmacother; 2008 May; 42(5):713-8. PubMed ID: 18397974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemfibrozil-induced myositis in a patient with normal renal function.
    Hahn M; Sriharan K; McFarland MS
    Ann Pharmacother; 2010 Jan; 44(1):211-4. PubMed ID: 19934390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic injury in a patient taking rosiglitazone.
    Menees SB; Anderson MA; Chensue SW; Moseley RH
    J Clin Gastroenterol; 2005 Aug; 39(7):638-40. PubMed ID: 16000935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
    Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
    Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle pain associated with daptomycin.
    Veligandla SR; Louie KR; Malesker MA; Smith PW
    Ann Pharmacother; 2004 Nov; 38(11):1860-2. PubMed ID: 15367725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine.
    Zou XJ; Jiang XQ; Tian DY
    J Viral Hepat; 2011 Dec; 18(12):892-6. PubMed ID: 22093034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinedione-induced congestive heart failure.
    Cheng AY; Fantus IG
    Ann Pharmacother; 2004 May; 38(5):817-20. PubMed ID: 15039476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creatine kinase elevation in a patient taking rosiglitazone.
    Sahin M; Bakiner O; Ertugrul D; Guvener ND
    Diabet Med; 2005 Nov; 22(11):1624-5. PubMed ID: 16241933
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.
    Page RL; Gozansky WS; Ruscin JM
    Pharmacotherapy; 2003 Jul; 23(7):945-54. PubMed ID: 12885108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
    Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
    Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
    Marceille JR; Goins JA; Soni R; Biery JC; Lee TA
    Pharmacotherapy; 2004 Oct; 24(10):1317-22. PubMed ID: 15628829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild, reversible pancytopenia induced by rosiglitazone.
    Maaravi Y; Stessman J
    Diabetes Care; 2005 Jun; 28(6):1536. PubMed ID: 15920093
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatic failure in a patient taking rosiglitazone.
    Forman LM; Simmons DA; Diamond RH
    Ann Intern Med; 2000 Jan; 132(2):118-21. PubMed ID: 10644272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular safety of rosiglitazone.
    Ajjan RA; Grant PJ
    Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.